Clinical trial
Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer
NCT02068794 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer
- Lead sponsor
- Mayo Clinic
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- April 25, 2014
- Completion date
- March 15, 2027
- Enrollment
- 34 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma, fallopian tube undifferentiated carcinoma, malignant ovarian brenner tumor, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian mucinous adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, ovarian undifferentiated carcinoma, primary peritoneal serous adenocarcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma